TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38987228

Group type: EXPERIMENTAL
Intervention: Eculizumab (intravenous infusion, once weekly for 4 weeks) with IVIg treatment
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo with IVIg treatment
Number of subjects: 57
Study: 38987291

Group type: EXPERIMENTAL
Intervention: Mixed meal tolerance test (MMTT)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Follow-up after median time 9.6 years
Number of subjects: 501
Study: 38987318

Group type: EXPERIMENTAL
Intervention: SVF isolated by the new clinical protocol
Number of subjects: 13

Group type: COMPARATOR
Intervention: SVF isolated by the laboratory protocol
Number of subjects: 13
Study: 38987363

Group type: EXPERIMENTAL
Intervention: Regorafenib (120 or 160 mg daily) given from day 4 to day 10 of each 14-day cycle of FOLFIRINOX (including oxaliplatin, folinic acid, fluorouracil, and irinotecan at 150 or 180 mg/m²)
Number of subjects: 13
Study: 38987407

Group type: EXPERIMENTAL
Intervention: Healthy School Start intervention
Number of subjects: 353
Study: 38987421

Group type: EXPERIMENTAL
Intervention: AMH ≥ 1.1 ng/mL
Number of subjects: 245

Group type: COMPARATOR
Intervention: AMH < 1.1 ng/mL
Number of subjects: 245
Study: 38987667

Group type: EXPERIMENTAL
Intervention: Head rotation technique
Number of subjects: 158
Study: 38987669

Group type: EXPERIMENTAL
Intervention: Discharge letter content with at least five of eleven key elements coded using an assessment matrix and deductive content analysis.
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Discharge letters containing all eleven key elements.
Number of subjects: 136
Study: 38987671

Group type: EXPERIMENTAL
Intervention: FX CorAL 600
Number of subjects: 82

Group type: COMPARATOR
Intervention: FX CorDiax 600
Number of subjects: 82

Group type: COMPARATOR
Intervention: xevonta Hi 15
Number of subjects: 82
Study: 38987676

Group type: EXPERIMENTAL
Intervention: Personalized care program
Number of subjects: 50

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 50
Study: 38987696

Group type: EXPERIMENTAL
Intervention: Extracorporeal cardiopulmonary resuscitation (ECPR)
Number of subjects: 648
Study: 38987721

Group type: EXPERIMENTAL
Intervention: Home-based filming for General Movement Assessment (GMA)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Hospital-based filming for General Movement Assessment (GMA)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Home filming experience
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Concerns about child development after home filming
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Perception of home video for GMA
Number of subjects: 102
Study: 38987737

Group type: EXPERIMENTAL
Intervention: Psychotherapy incorporating horses (PIH) during 15 sessions once a week.
Number of subjects: 35
Study: 38987784

Group type: EXPERIMENTAL
Intervention: Coenzyme-Q10 (240 mg daily)
Number of subjects: 60
Study: 38987786

Group type: EXPERIMENTAL
Intervention: Combined usage of povidone-iodine irrigation and topical vancomycin powder before wound closure
Number of subjects: 840

Group type: COMPARATOR
Intervention: Povidone-iodine irrigation alone before wound closure
Number of subjects: 840
Study: 38987812

Group type: EXPERIMENTAL
Intervention: Prepare Romania (culturally adapted counseling and mobile health intervention)
Number of subjects: 120

Group type: COMPARATOR
Intervention: PrEP education control arm
Number of subjects: 120
Study: 38988185

Group type: EXPERIMENTAL
Intervention: Govorestat 5 mg/kg
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Govorestat 20 mg/kg
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Govorestat 40 mg/kg
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 38988248

Group type: EXPERIMENTAL
Intervention: Pre-operative transthoracic echocardiography (TTE) recommendations
Number of subjects: 15529

Group type: EXPERIMENTAL
Intervention: Pre-operative stress imaging recommendations
Number of subjects: 15529

Group type: EXPERIMENTAL
Intervention: Adherence to pre-operative stress imaging recommendations
Number of subjects: 15529

Group type: EXPERIMENTAL
Intervention: Adherence to pre-operative TTE recommendations
Number of subjects: 15529

Group type: COMPARATOR
Intervention: Factors affecting adherence
Number of subjects: 15529
Study: 38988285

Group type: EXPERIMENTAL
Intervention: ASC10 (50-800 mg, twice daily for 5.5 days)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 38988455

Group type: EXPERIMENTAL
Intervention: Psilocybin therapy
Number of subjects: 10
Study: 38988736

Group type: EXPERIMENTAL
Intervention: EMDR intervention for 8 weeks
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (no EMDR intervention)
Number of subjects: 107
Study: 38988743

Group type: EXPERIMENTAL
Intervention: Ultrasonic scaling
Number of subjects: 38
Study: 38989287

Group type: EXPERIMENTAL
Intervention: Active treatment (mannan-allergoid conjugates) via subcutaneous (SC) and sublingual (SL) routes at doses of 500, 1,000, 3,000, or 5,000 mTU/mL
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo (bot SC and SL placebo)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Active treatment (mannan-allergoid conjugates) via SC
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Active treatment (mannan-allergoid conjugates) via SL
Number of subjects: 162
Study: 38989414

Group type: EXPERIMENTAL
Intervention: PDS01ADC in combination with floxuridine delivered via a hepatic artery infusion pump (HAIP)
Number of subjects: 0
Study: 38989575

Group type: EXPERIMENTAL
Intervention: Fenestrated-branched endovascular aortic repair (FB-EVAR)
Number of subjects: 1109
Study: 38989869

Group type: EXPERIMENTAL
Intervention: FMT with RCE
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo with RCE
Number of subjects: 110
Study: 38989889

Group type: EXPERIMENTAL
Intervention: EC/EG test
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: EC test
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Spielberger State-Trait Anxiety Inventory-6
Number of subjects: 124
Study: 38990016

Group type: EXPERIMENTAL
Intervention: GST-HG171; single-dose administration; specific dosage not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy subjects; single-dose administration of GST-HG171; specific dosage not mentioned.
Number of subjects: 0
Study: 38990090

Group type: EXPERIMENTAL
Intervention: Dostarlimab with chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 38990195

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel plus S-1 (AS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Nab-paclitaxel plus gemcitabine (AG)
Number of subjects: 62
Study: 38990234

Group type: EXPERIMENTAL
Intervention: Reduced distance best-corrected visual acuity
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Minority race
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Increased self-efficacy
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Better physical function
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Increased loneliness
Number of subjects: 114
Study: 38990239

Group type: EXPERIMENTAL
Intervention: 100Δ oblique multiperiscopic prisms (≈42° expansion)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 65Δ oblique Fresnel peripheral prisms (≈32° expansion)
Number of subjects: 6

Group type: COMPARATOR
Intervention: No prisms
Number of subjects: 6
Study: 38990250

Group type: EXPERIMENTAL
Intervention: Invasive approach (routine coronary angiography and fractional flow reserve-guided revascularization)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Conservative approach (optimal medical therapy alone)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Invasive approach
Number of subjects: 185

Group type: COMPARATOR
Intervention: Conservative approach
Number of subjects: 185
Study: 38990433

Group type: EXPERIMENTAL
Intervention: Momelotinib
Number of subjects: 156

Group type: COMPARATOR
Intervention: BAT/ruxolitinib
Number of subjects: 156
Study: 38990545

Group type: EXPERIMENTAL
Intervention: Youth sport practice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38990564

Group type: EXPERIMENTAL
Intervention: Ultralow-dose radiation therapy to 4 Gy in 2 fractions, with an additional 20 Gy in 10 fractions for persistent cases.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ultralow-dose radiation therapy to 4 Gy in 2 fractions.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ultralow-dose radiation therapy to 4 Gy in 2 fractions for newly diagnosed, untreated stage I mucosa-associated lymphoid tissue lymphoma.
Number of subjects: 50
Study: 38990638

Group type: EXPERIMENTAL
Intervention: Eumenorrheic group (n=20)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive pill (COCP) users (n=20)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Nonhormonal contraceptive users (n=20)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Hormonal implant users (n=20)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Hormonal intrauterine system users (n=20)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Hormonal injection users (n=20)
Number of subjects: 66
Study: 38990692

Group type: EXPERIMENTAL
Intervention: Self-compassion enhancement through brief, mindfulness-based psychotherapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noninterpersonal trauma exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physical trauma exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sexual trauma exposure
Number of subjects: 0
Study: 38990808

Group type: EXPERIMENTAL
Intervention: Mini-KIDS
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Social Cognitive Behaviour Treatment (SCBT)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Lidcombe Program
Number of subjects: 249
Study: 38990927

Group type: EXPERIMENTAL
Intervention: ILB® (low molecular weight dextran sulphate) administered at a dosage of 2 mg/kg weekly for up to 38 weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: ILB® treatment
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Long-term follow-up after ILB® treatment
Number of subjects: 11
Study: 38991011

Group type: EXPERIMENTAL
Intervention: Facial cleanliness measures (wet nasal discharge, dry nasal discharge, wet ocular discharge, dry ocular discharge, food, dust/dirt, flies) assessed by masked photo-graders.
Number of subjects: 2073

Group type: EXPERIMENTAL
Intervention: Dry ocular discharge
Number of subjects: 2073

Group type: EXPERIMENTAL
Intervention: Clinically active trachoma
Number of subjects: 2073

Group type: EXPERIMENTAL
Intervention: Ocular chlamydia infection
Number of subjects: 2073
Study: 38991123

Group type: EXPERIMENTAL
Intervention: Tipifarnib 300 mg orally twice daily for 21 days in a 28-day cycle
Number of subjects: 65
Study: 38991137

Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech vaccine (2 doses)
Number of subjects: 41
Study: 38991197

Group type: EXPERIMENTAL
Intervention: Rhythmic and periodic patterns (RPPs) on EEG
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Sufficient EEG background continuity before and during RPPs
Number of subjects: 172
Study: 38991216

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection during pregnancy
Number of subjects: 1502

Group type: COMPARATOR
Intervention: History of obesity
Number of subjects: 1502

Group type: COMPARATOR
Intervention: History of depression or anxiety disorder
Number of subjects: 1502

Group type: COMPARATOR
Intervention: Economic hardship (self-reported difficulty covering expenses)
Number of subjects: 1502

Group type: COMPARATOR
Intervention: Treatment with oxygen during acute SARS-CoV-2 infection
Number of subjects: 1502
Study: 38991582

Group type: EXPERIMENTAL
Intervention: Digital ACT (n=140)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Active control (n=135)
Number of subjects: 275
Study: 38991631

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38991672

Group type: EXPERIMENTAL
Intervention: Standardised Nutritional and Psycho-Behavioural Rehabilitation programme (RNPC Programme)
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Standardised RNPC Programme
Number of subjects: 10000
Study: 38991671

Group type: EXPERIMENTAL
Intervention: Intervention components for habit formation including stable routines, planning, external reminders, and extrinsic motivation.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Conditional financial incentives to support habit formation.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Feedback on study components including text size and visual appeal of habit leaflet.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Experiencing medication side effects.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Contextual factors such as frequent changes to prescription and polypharmacy.
Number of subjects: 27
Study: 38991682

Group type: EXPERIMENTAL
Intervention: 10-Hz transcranial alternating current stimulation (tACS) at 1 mA intensity, 20 min duration, repeated over five consecutive days.
Number of subjects: 138

Group type: COMPARATOR
Intervention: Sham session over parieto-occipital cortical sites, repeated over five consecutive days.
Number of subjects: 138
Study: 38991704

Group type: EXPERIMENTAL
Intervention: CYPHP population health management system
Number of subjects: 129412
Study: 38991714

Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine 0.2% + 2 µg/mL epinephrine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine 0.2% + 5 µg/mL epinephrine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Epidural ropivacaine 0.2% without epinephrine (control)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study: 38991950

Group type: EXPERIMENTAL
Intervention: Geographically targeted active case finding using MATCH-AI software
Number of subjects: 30

Group type: COMPARATOR
Intervention: Existing approaches towards site selection based on staff knowledge and historical data
Number of subjects: 30
Study: 38992025

Group type: EXPERIMENTAL
Intervention: Lower plasma levels of VEGF-A
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Lower plasma levels of angiopoietin-2
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Genetic variant rs6770663 in KCNAB1
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Combination of protein levels and rs6770663
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Protein levels of VEGF-A, angiopoietin-2 and rs6770663 in KCNAB1
Number of subjects: 277
Study: 38992116

Group type: EXPERIMENTAL
Intervention: Automated four-chamber CMR analysis
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Automated four-chamber CMR analysis with correction factors
Number of subjects: 101

Group type: COMPARATOR
Intervention: Left atrial ejection fraction (manual analysis)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Left atrial ejection fraction (AI analysis)
Number of subjects: 101
Study: 38992123

Group type: EXPERIMENTAL
Intervention: benmelstobart and anlotinib plus etoposide/carboplatin (EC)
Number of subjects: 738

Group type: COMPARATOR
Intervention: anlotinib plus etoposide/carboplatin (EC)
Number of subjects: 738

Group type: COMPARATOR
Intervention: EC alone
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: benmelstobart and anlotinib plus EC
Number of subjects: 738

Group type: COMPARATOR
Intervention: anlotinib plus EC
Number of subjects: 738
Study: 38992129

Group type: EXPERIMENTAL
Intervention: Adoptive cell transfer (ACT) with neoantigen-reactive T lymphocytes
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: T cell populations containing ≥50% TCR-transduced cells
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: TCR-transduced cells
Number of subjects: 7
Study: 38992490

Group type: EXPERIMENTAL
Intervention: LABA/ICS
Number of subjects: 0

Group type: COMPARATOR
Intervention: LABA/LAMA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BEC measured on ICS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BEC off ICS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BEC change during ICS treatment
Number of subjects: 0
Study: 38992663

Group type: EXPERIMENTAL
Intervention: Restrictive fluid management
Number of subjects: 196

Group type: COMPARATOR
Intervention: Liberal fluid management
Number of subjects: 196
Study: 38992713

Group type: EXPERIMENTAL
Intervention: empagliflozin
Number of subjects: 7020

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7020
Study: 38993008

Group type: EXPERIMENTAL
Intervention: Soticlestat (TAK-935) 300 mg single oral dose
Number of subjects: 35
Study: 38993026

Group type: EXPERIMENTAL
Intervention: Avacopan 30 mg single oral dose in patients with mild hepatic impairment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Avacopan 30 mg single oral dose in patients with moderate hepatic impairment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal hepatic function (control group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Metabolite M1 in patients with mild or moderate hepatic impairment
Number of subjects: 24
Study: 38993150

Group type: EXPERIMENTAL
Intervention: SAR442085 (5-7.5 mg/kg)
Number of subjects: 37
Study: 38993694

Group type: EXPERIMENTAL
Intervention: Network-based Cognitive Training (NBCT)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Home-based Cognitive Rehabilitation (HomeCoRe)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Semantic Memory Rehabilitation Training (SMRT)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study: 38993854

Group type: EXPERIMENTAL
Intervention: Everolimus plus Tacrolimus (EVR/TAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mycophenolic Acid plus Tacrolimus (MPA/TAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Everolimus plus Cyclosporine A (EVR/CsA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mycophenolic Acid plus Cyclosporine A (MPA/CsA)
Number of subjects: 0
Study: 38993983

Group type: EXPERIMENTAL
Intervention: Once-weekly HIIT (75 min, 16 weeks)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Thrice-weekly HIIT (75 min, 16 weeks)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 315
Study: 38994348

Group type: EXPERIMENTAL
Intervention: MDMA-assisted brief cognitive behavioral conjoint therapy (bCBCT)
Number of subjects: 8
Study: 38994465

Group type: EXPERIMENTAL
Intervention: Public health insurance coverage
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Mastectomy, adenomastectomy or skin-sparing mastectomy
Number of subjects: 599

Group type: COMPARATOR
Intervention: Breast-conserving surgery
Number of subjects: 599
Study: 38994536

Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline (Hypersal) intravesical instillation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study: 38994833

Group type: EXPERIMENTAL
Intervention: Fecal Immunochemical Test (FIT)
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: Fecal Calprotectin (FC)
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: C-Reactive Protein (CRP)
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: Combination of stool tests with alarm features
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: Alarm features
Number of subjects: 922
Study: 38995189

Group type: EXPERIMENTAL
Intervention: Robotic transmitral approach
Number of subjects: 0
Study: 38995194

Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitoring (HBPM)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Clinic Blood Pressure (BP) Measurement
Number of subjects: 35

Group type: COMPARATOR
Intervention: Kiosk BP Diagnostic Testing
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ambulatory Blood Pressure Monitoring (ABPM)
Number of subjects: 35
Study: 38995237

Group type: EXPERIMENTAL
Intervention: Talazoparib plus enzalutamide
Number of subjects: 805

Group type: COMPARATOR
Intervention: Placebo plus enzalutamide
Number of subjects: 805
Study: 38995311

Group type: EXPERIMENTAL
Intervention: Vimseltinib, 30 mg twice weekly
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Vimseltinib
Number of subjects: 32
Study: 38995327

Group type: EXPERIMENTAL
Intervention: CPAP adherence (hours/night)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: CPAP efficacy (apneas-hypopneas/hour)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Sleep quality
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Sleepiness
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Insomnia
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Neurocognitive function
Number of subjects: 267
Study: 38995409

Group type: EXPERIMENTAL
Intervention: Distal resection margin distance < 3 cm
Number of subjects: 1958

Group type: EXPERIMENTAL
Intervention: Distal resection margin distance ≥ 6 cm
Number of subjects: 1958

Group type: EXPERIMENTAL
Intervention: Advanced N stage
Number of subjects: 1958

Group type: EXPERIMENTAL
Intervention: Number of lymph nodes dissected (less number)
Number of subjects: 1958

Group type: EXPERIMENTAL
Intervention: Anastomotic recurrence (AR) group
Number of subjects: 1958

Group type: EXPERIMENTAL
Intervention: Radical surgery for AR
Number of subjects: 1958
Study: 38995504

Group type: EXPERIMENTAL
Intervention: 1.5% ruxolitinib cream (continuous-use)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 1.5% ruxolitinib cream (as-needed use)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 78
Study: 38995646

Group type: EXPERIMENTAL
Intervention: Screen media reduction intervention (reduced to 3 hours per week or less)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Screen media reduction intervention
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 181
Study: 38995684

Group type: EXPERIMENTAL
Intervention: TAK-003 (live-attenuated tetravalent dengue vaccine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38995690

Group type: EXPERIMENTAL
Intervention: Imlifidase (IgG endopeptidase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-IL-6 receptor (tocilizumab) or anti-IL-6 (clazakizumab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-CD38 and anti-B-cell maturation antigen×CD3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complement inhibitors and novel agents aimed at inhibiting Fc neonatal receptor IgG recycling
Number of subjects: 0
Study: 38996086

Group type: EXPERIMENTAL
Intervention: Emergency Department Code Sepsis Protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38996196

Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 600